Primary Aldosteronism Due to Aldosterone Producing Adenoma Clinical Trial
Official title:
Spatial Proteomics Profiles of Adrenal Adenoma/Hyperplasia Leading to Primary Aldosterone
Primary aldosteronism (PA) is a common cause of secondary hypertension, which is characterized by excessive aldosterone production by the adrenal gland. Excessive aldosterone can significantly increase the risk of cardiovascular disease and stroke. Patients with aldosterone-producing adenoma (APA) or unilateral hyperplasia (UAH) can be cured by unilateral adrenalectomy. The adrenal cortex is the outer part of the adrenal gland and is subdivided into three layers- the zona glomerulosa, the zona fasciculata, and the zona reticularis. And the outermost layer is the zona glomerulosa, and it's full of cells that make the hormone aldosterone. Although it has been investigated that the main cause of APA or UAH is the mutations of different calcium ion channels, including KCNJ5, CACNA1D, CLCN2 et al, it is still unknown whether there are any other changes of other proteins in different layers. Therefore, the investigators designed the study to characterize the proteomics profiles of adrenal adenoma/hyperplasia leading to primary aldosterone and identify biomarkers for early identification of PA by using spatial proteomics. The samples from adrenal adenoma or hyperplasia will be collected and analyzed by spatial proteomics in Hangzhou Jingjie Biotechnology Co., Ltd. The differentially expressed proteins in different layers will be screened out between APA and UAH, APA and its adjacent normal tissues, and UAH and its adjacent normal tissues, respectively. And KEGG analysis will be conducted to determine enriched pathway in these differentially expressed protein, respectively.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05361083 -
First-in-human Evaluation of [18F]CETO
|
Early Phase 1 | |
| Recruiting |
NCT04428827 -
Outcome of Patients With Primary Aldosteronism
|
||
| Completed |
NCT03990701 -
Primary Aldosteronism and Surgically Curable Forms in Hypertension Patients Using 11C-Metomidate
|
Early Phase 1 | |
| Completed |
NCT04761354 -
Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis
|
||
| Completed |
NCT04185857 -
MRA and ARB Treatment in Screening of Primary Aldosteronism
|
||
| Completed |
NCT04378387 -
Ipsilateral and Contralateral Index for the Interpretation of Adrenal Vein Sampling (AVS) in Primary Aldosteronism
|
||
| Completed |
NCT03174847 -
Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism
|
||
| Recruiting |
NCT06100367 -
11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours
|
Phase 2/Phase 3 | |
| Completed |
NCT02642445 -
Renal Sympathetic Denervation From The Adventitia on Hypertension
|
N/A | |
| Not yet recruiting |
NCT03449797 -
Rapid Cortisol Assay in Adrenal Vein Sampling
|
N/A |